Table 3.
Immunomodulation by MSCs and TAFs.
| Tumor entity | Effects observed | Effects mediated by | Literature |
|---|---|---|---|
| Cervical cancer | Downregulation of HLA-I in cervical cancer by T-MSCs cell lines and reduced cytolysis by CTL-cells | IL-10 |
[26] |
|
| |||
| Melanoma | Impairment of NK cell answer against melanoma cells by reduced upregulation of NKp44, NKp33, and DNAMI after exposure to T-MSCs | (i) Reduction of NKp44 and expression (mediated by PGE2) (ii) Reduction of DNAMI expression (depending on cell to cell contact) |
[64, 65] |
|
| |||
| Pancreatic cancer | Depletion of arginine renders tumor infiltrating T cells dysfunctional | Expression of ARG2 and arginine depletion | [66] |
|
| |||
| NSCLC | CD3/CD28 depending activation of T cells | IL-6 | [67] |
|
| |||
| Follicular lymphoma | MSCs from follicular lymphoma patients display increased recruitment of TAM and a distinct gene expression profile | Overexpression of CCL2 | [68] |